The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study
- 25 June 2007
- journal article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 40 (5), 443-450
- https://doi.org/10.1038/sj.bmt.1705752
Abstract
Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous subset of lymphomas with a poorer prognosis compared with B-cell lymphomas. We conducted a retrospective study of 82 patients who received high-dose therapy for PTCL (autologous SCT (ASCT) N=64; allogeneic SCT (Allo-SCT) N=18). With a median follow-up from ASCT of 37 months from transplant, 33 patients were alive; 20 died of progressive disease, 10 died from non-relapse mortality (NRM) with 1 unknown cause. Three-year overall survival (OS) and progression-free survival (PFS) were 53% (95% confidence interval (CI) 42, 67) and 50% (95% CI 39, 64), respectively. Factors significantly affecting OS and PFS on univariate analysis were histological subtype and chemotherapy sensitivity. In a multivariate analysis, the only factor with significant impact was chemotherapy sensitivity. After a median follow-up from Allo-SCT of 57 months, five patients were alive; five died of progressive disease and eight died from NRM. The 3-year OS and PFS were 39% (95% CI 22, 69) and 33% (95% CI 17, 64), respectively, and the 3-year relapse rate was 28% (95% CI 6, 50). These results demonstrate that high-dose chemotherapy with autologous stem cell rescue has a substantial role in the management of T-cell lymphoma. The use of full-intensity allogeneic transplantation is limited by high transplant-related mortality, and exploration of reduced intensity regimens is warranted.Keywords
This publication has 24 references indexed in Scilit:
- Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphomaBritish Journal of Haematology, 2006
- Histology Impacts the Outcome of Peripheral T-Cell Lymphomas after High Dose Chemotherapy and Stem Cell TransplantLeukemia & Lymphoma, 2004
- Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic CellsJournal of Clinical Oncology, 2004
- High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphomaBone Marrow Transplantation, 2004
- Impact of High-Dose Chemotherapy on Peripheral T-Cell LymphomasJournal of Clinical Oncology, 2001
- High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomasBone Marrow Transplantation, 2001
- Allogeneic bone marrow transplantation in patients who relapse after autologous transplantationBone Marrow Transplantation, 1997
- Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimenAnnals of Oncology, 1990
- Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1989
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988